RemeGen Co., Ltd. (SHA:688331)
China · Delayed Price · Currency is CNY 107.40
-2.77 (-2.51%)
Sep 12, 2025, 3:00 PM CST
RemeGen Revenue
RemeGen had revenue of 571.98M CNY in the quarter ending June 30, 2025, with 39.06% growth. This brings the company's revenue in the last twelve months to 2.07B, up 47.83% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
2.07B
Revenue Growth
+47.83%
P/S Ratio
28.09
Revenue / Employee
675.26K
Employees
2,999
Market Cap
58.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| WuXi AppTec | 41.90B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Shanghai United Imaging Healthcare | 10.98B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.94B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |